Market Place
Sourcing Support
F2G Secures $100M For Olorofim Development And Commercialization
12 Sep 2024 //
GLOBENEWSWIRE
F2G Receives CRL from FDA for New Drug Application for Olorofim
20 Jun 2023 //
FINANCE YAHOO
F2G Receives CRL from FDA for NDA for Olorofim for The Treatment
19 Jun 2023 //
PRESS RELEASE
F2G to Present Interim Results from Phase 2B Open Label Study of Olorofim
13 Oct 2022 //
GLOBENEWSWIRE
Novo Holdings, Shionogi offer treatment for invasive fungal infections
16 May 2022 //
BIOSPECTRUMASIA
F2G`s Olorofim Receives Both FDA Orphan Drug Designation for Coccidioidomycosis
09 Jun 2020 //
PRNEWSWIRE
F2G Receives US FDA Breakthrough Therapy Designation for Olorofim
11 Nov 2019 //
PR NEWSWIRE
F2G Receives US FDA Breakthrough Therapy Designation for Olorofim
11 Nov 2019 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.